Last quarter (Q3 2023), Alaunos Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q3, Alaunos Therapeutics's net income was $-6.45M. See Alaunos Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ -7.00K	$ 2.90M	$ 400.00K	$ 0.00	$ 0.00	$ 146.00K
Cost of Revenue	-	-	$ 0.00	-	-	-
Gross Profit	$ -7.00K	$ 2.90M	$ 400.00K	-	-	-
Operating Expense	$ 17.79M	$ 38.03M	$ 77.95M	$ 80.36M	$ 57.86M	$ 54.05M
Operating Income	$ -35.35M	$ -35.10M	$ -77.55M	$ -80.36M	$ -57.86M	$ -53.91M
Net Non Operating Interest Income Expense	$ -4.24M	$ -3.15M	$ -1.19M	$ 0.00	-	-
Other Income Expense	$ -1.22M	$ -529.00K	$ 13.00K	$ 385.00K	$ -59.94M	$ 789.00K
Pretax Income	$ -35.65M	$ -38.02M	$ -78.75M	$ -79.98M	$ -117.80M	$ -53.12M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -35.16M	$ -38.02M	$ -78.75M	$ -79.98M	$ -117.80M	$ 137.25M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 17.79M	$ 38.03M	$ 77.95M	$ 80.36M	$ 57.86M	$ 54.05M
Net Income From Continuing And Discontinued Operation	$ -37.18M	$ -37.73M	$ -78.75M	$ -79.98M	$ -117.80M	$ -53.12M
Normalized Income	$ -12.00M	$ -30.03M	-	$ -79.98M	$ -57.05M	$ -53.27M
Interest Expense	-	-	-	$ 0.00	-	-
EBIT	$ -31.41M	$ -34.86M	$ -77.56M	$ -79.98M	$ -57.86M	$ -53.91M
EBITDA	$ -26.92M	$ -31.08M	$ -74.58M	$ -78.85M	$ -57.23M	$ -53.33M

Currency in USD

Alaunos Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing